Literature DB >> 7825344

Pain pathways and transmission.

L M Kitahata1.   

Abstract

Pain has been a major concern of humankind since the ancient times, and it remains one of the most important subjects of all health care professionals. Despite the obvious overwhelming clinical importance, the major advances in its diagnosis and therapy have been made only recently. "How do the sensory apparatus of the body and system of signal transmission relate to pain of peripheral origin?" is the topic of discussion. To do this, it is important to understand what constitutes the total pain experience. It consists of: 1) signal transduction at the peripheral receptor site, 2) signal conduction along the peripheral nerve, 3) pain modulation at the level of the spinal cord, 4) pain perception at the supraspinal site, and 5) the associated sensations, emotional reactions, and effective state. The signal transmission related to pain may be modified by various analgesic agents. Specific analgesic agent has a specific site of action which may be at peripheral receptors, at peripheral nerves, at the level of the spinal cord, at supraspinal levels by activating descending inhibitory systems, or at more cephalad levels by reducing the affective component of pain.

Entities:  

Mesh:

Year:  1993        PMID: 7825344      PMCID: PMC2588883     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  41 in total

1.  PRESYNAPTIC HYPERPOLARIZATION: A ROLE FOR FINE AFFERENT FIBRES.

Authors:  L M MENDELL; P D WALL
Journal:  J Physiol       Date:  1964-08       Impact factor: 5.182

2.  Interaction between opiate subtype and alpha-2 adrenergic agonists in suppression of noxiously evoked activity of WDR neurons in the spinal dorsal horn.

Authors:  K Omote; L M Kitahata; J G Collins; K Nakatani; I Nakagawa
Journal:  Anesthesiology       Date:  1991-04       Impact factor: 7.892

3.  Lamina-specific suppression of dorsal-horn unit activity by morphine sulfate.

Authors:  L M Kitahata; Y Kosaka; A Taub; K Bonikos; M Hoffert
Journal:  Anesthesiology       Date:  1974-07       Impact factor: 7.892

4.  Lamina-specific suppression of dorsal-horn unit activity by detamine hydrochloride.

Authors:  L M Kitahata; A Taub; Y Kosada
Journal:  Anesthesiology       Date:  1973-01       Impact factor: 7.892

Review 5.  Spinal action of narcotic analgesics.

Authors:  L M Kitahata; J G Collins
Journal:  Anesthesiology       Date:  1981-02       Impact factor: 7.892

6.  Spinal analgesia with morphine and clonidine.

Authors:  L M Kitahata
Journal:  Anesth Analg       Date:  1989-03       Impact factor: 5.108

7.  Lack of opiate effects on cat C polymodal nociceptive fibers.

Authors:  Masaki Senami; Mitsuru Aoki; Luke M Kitahata; J G Collins; Yukihiro Kumeta; Kenji Murata
Journal:  Pain       Date:  1986-10       Impact factor: 6.961

8.  Analgesia from electrical stimulation in the brainstem of the rat.

Authors:  D J Mayer; T L Wolfle; H Akil; B Carder; J C Liebeskind
Journal:  Science       Date:  1971-12-24       Impact factor: 47.728

9.  Postoperative pain after inguinal herniorrhaphy with different types of anesthesia.

Authors:  M Tverskoy; C Cozacov; M Ayache; E L Bradley; I Kissin
Journal:  Anesth Analg       Date:  1990-01       Impact factor: 5.108

10.  Analgesia mediated by a direct spinal action of narcotics.

Authors:  T L Yaksh; T A Rudy
Journal:  Science       Date:  1976-06-25       Impact factor: 47.728

View more
  3 in total

1.  Factors Determining Outcome After Surgery for Chronic Groin Pain Following a Lichtenstein Hernia Repair.

Authors:  Willem A R Zwaans; Tim Verhagen; Rudi M H Roumen; Marc R M Scheltinga
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

Review 2.  Pain and the pathogenesis of biceps tendinopathy.

Authors:  Elise B Raney; Finosh G Thankam; Matthew F Dilisio; Devendra K Agrawal
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

3.  Spinal versus general anaesthesia in surgery for inguinodynia (SPINASIA trial): study protocol for a randomised controlled trial.

Authors:  Willem A R Zwaans; Léon H P M le Mair; Marc R M Scheltinga; Rudi M H Roumen
Journal:  Trials       Date:  2017-01-14       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.